(0)サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1737556

慢性腎臓病治療の世界市場

Chronic Kidney Disease Treatment

出版日
ページ情報
英文 281 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.58円
慢性腎臓病治療の世界市場
出版日: 2025年05月30日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 281 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

慢性腎臓病治療の世界市場は2030年までに172億米ドルに達する見込み

2024年に145億米ドルと推定される慢性腎臓病治療の世界市場は、2024年から2030年にかけてCAGR 2.9%で成長し、2030年には172億米ドルに達すると予測されます。本レポートで分析したセグメントの一つである医薬品は、CAGR 2.1％を記録し、分析期間終了時には109億米ドルに達すると予測されます。透析分野の成長率は、分析期間中CAGR 4.3%と推定されます。

米国市場は40億米ドル、中国はCAGR 5.4％で成長すると予測

米国の慢性腎臓病治療市場は2024年に40億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに33億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは5.4%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.2%と2.2%と予測されています。欧州では、ドイツがCAGR 1.6%で成長すると予測されています。

世界の慢性腎臓病治療市場- 主要動向と促進要因まとめ

なぜ慢性腎臓病は優先度の高い世界の健康負担として浮上しているのか？

慢性腎臓病（CKD）は、世界中で8億5,000万人以上が罹患し、死亡率および障害調整生存年数の上位を占めるなど、公衆衛生上の緊急課題となっています。CKDは糖尿病、高血圧、心血管障害と強い関連があり、人口の高齢化も相まって、世界の流行が続いています。初期段階のCKDは無症状のままであることが多いため、診断が遅れ、末期腎不全（ESRD）に進行すると、長期にわたる透析や臓器移植が必要となり、医療システムに臨床的・経済的に大きな負担を強いることになります。

政府や保健機関は、慢性的な経過、高い治療費、労働生産性への影響から、非感染性疾患（NCD）戦略の中でCKDを優先しています。予防的腎臓学と早期介入へのシフトは、疾患の進行を遅らせ、併存疾患を管理し、貧血、高リン血症、ミネラル骨障害などの合併症を軽減する治療法への需要を強めています。また、特に高リスク集団において、早期診断と治療への参加を促進するための啓発キャンペーンやスクリーニングプログラムも拡大しています。

薬理学的進歩とマルチターゲット治療はCKD治療アプローチをどのように形成しているか？

薬理学的な革新はCKD治療のパラダイムを再構築しており、症状の管理だけでなく疾患修飾経路を標的とする新規薬剤の強力なパイプラインがあります。ナトリウム-グルコース共輸送体-2（SGLT2）阻害薬は血糖コントロールだけでなく、糖尿病患者および非糖尿病患者の両方のCKD患者における腎保護作用や心血管保護作用でも注目されています。これらの薬剤は、非ステロイド性ミネラルコルチコイド受容体拮抗薬（nsMRA）やエンドセリン受容体拮抗薬とともに、従来のACE阻害薬やARB以外の治療選択肢を広げています。

炎症、酸化ストレス、蛋白尿などCKD進行の多因子性に対処するために、併用療法の導入が進んでいます。一方、低酸素誘導因子プロリル水酸化酵素阻害薬（HIF-PHI）などの次世代の貧血治療薬の開発により、赤血球造血刺激因子製剤に伴うリスクを伴わずにCKDに関連した貧血の治療成績が向上しています。このマルチターゲットアプローチは、腎機能維持と長期的リスク軽減を重視した、より個別化された疾患特異的レジメンへとCKD治療を前進させています。

どのようなデリバリーモデルと技術がCKD治療へのアクセスと継続性を支えているか？

ヘルスケアシステムが早期のCKD管理を優先する中、プライマリケア、腎臓内科、栄養学、行動衛生学を含む統合ケア提供モデルが支持を集めています。このような集学的プログラムは、協調的でプロトコール主導の介入を通じて、疾患の進行を遅らせ、心血管合併症の管理を最適化することを目的としています。透析センターもまた、在宅腹膜透析や血液透析のオプションを提供するように進化しており、患者の自主性を支援し、施設ベースのケアインフラに対する物流負担を軽減しています。

遠隔モニタリングプラットフォーム、予測分析機能付き電子カルテ、遠隔腎臓学などのデジタルヘルスツールは、地域を超えたケアの継続性を向上させています。これらのテクノロジーは、機能低下の早期発見、リアルタイムの服薬遵守モニタリング、タイムリーな治療調整を可能にします。資源が限られた環境では、モバイルヘルス（mヘルス）アプリや携帯型診断機器が、特に腎臓専門医不足が深刻な農村部や十分な医療を受けていない人々の腎臓内科治療や教育へのアクセスを拡大しています。

支払者と政策立案者は、CKD治療の高い経済的負担にどのように対処しているか？

CKDは世界的に見ても患者一人当たりのヘルスケアコストが最も高い疾患の一つであり、特に透析と移植が支出の大半を占める末期にはその傾向が顕著です。ESRDの割合が上昇するにつれ、公的および民間の支払者は、早期介入にインセンティブを与え、費用対効果の高い治療を促進し、透析開始を遅らせるために、診療報酬の枠組みを再評価しています。CKD管理における患者の転帰と医療提供者のインセンティブを一致させるために、バンドルペイメントモデルやバリューベースケア契約が試験的に導入されています。

また、政策的措置として、新薬の国内処方や償還制度への組み入れなど、必須医薬品へのアクセス拡大も進められています。一部の地域では、政府がCKD登録、リスク層別化ツール、医療監督と資源配分を改善するための質指標に投資しています。患者擁護団体や製薬メーカーとのセクターを超えた協力により、CKDを「静かな伝染病」から「積極的に管理される慢性疾患」へと移行させることを目的とした、薬剤の購入しやすい価格設定プログラムや一般市民への教育イニシアチブが支援されています。

慢性腎臓病治療市場は、世界の格差に対処しながら、成果中心のイノベーションを推進できるか？

CKD治療を前進させる道は、イノベーションと公平性のバランスをとることにあります。つまり、新しい治療法、診断ツール、集学的ケアの枠組みが、あらゆる経済層や医療制度の患者に行き届くようにすることです。治療プロトコールがより洗練され、データ駆動型になるにつれ、ヘルスケア利害関係者は、特に診断率が低いままであり、腎代替療法がほとんどの患者にとって手の届かないものである中低所得国において、アクセスにおける根強い格差に対処しなければならないです。

持続可能な効果を達成するためには、人材育成、デジタルインフラ、公衆衛生サーベイランス、政策改革への投資が必要となります。腎保護療法や全人的な疾患管理モデルに対する臨床的エビデンスが高まるにつれ、中心的な疑問が浮かび上がってきます。世界のCKD治療市場は、新たな科学、人口動態の変化、システムレベルの圧力に適応しつつ、長期的な人的・財政的コストを軽減するために、公平でアウトカム志向の治療を迅速に拡大できるのだろうか？

セグメント

治療タイプ（薬剤タイプ、透析）、エンドユーザー（病院＆クリニック、透析センター、その他のエンドユーザー）

調査対象企業の例（合計47社に注目）

  • AbbVie Inc.
  • Akebia Therapeutics, Inc.
  • Allena Pharmaceuticals
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Cincor Pharma, Inc.
  • DiaMedica Therapeutics Inc.
  • Eli Lilly and Company
  • Fresenius Medical Care AG & Co. KGaA
  • GlaxoSmithKline plc
  • Kibow Biotech, Inc.
  • Lexicon Pharmaceuticals, Inc.
  • Monogram Health
  • Novo Nordisk A/S
  • ProKidney Corp.
  • Reata Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Strive Health

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP33615

Global Chronic Kidney Disease Treatment Market to Reach US$17.2 Billion by 2030

The global market for Chronic Kidney Disease Treatment estimated at US$14.5 Billion in the year 2024, is expected to reach US$17.2 Billion by 2030, growing at a CAGR of 2.9% over the analysis period 2024-2030. Drugs, one of the segments analyzed in the report, is expected to record a 2.1% CAGR and reach US$10.9 Billion by the end of the analysis period. Growth in the Dialysis segment is estimated at 4.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.0 Billion While China is Forecast to Grow at 5.4% CAGR

The Chronic Kidney Disease Treatment market in the U.S. is estimated at US$4.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.3 Billion by the year 2030 trailing a CAGR of 5.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 2.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Global Chronic Kidney Disease Treatment Market - Key Trends & Drivers Summarized

Why Is Chronic Kidney Disease Emerging as a High-Priority Global Health Burden?

Chronic Kidney Disease (CKD) is becoming an increasingly urgent public health concern, affecting over 850 million individuals worldwide and ranking among the top causes of mortality and disability-adjusted life years. The disease’s strong association with diabetes, hypertension, and cardiovascular disorders-coupled with rising aging populations-continues to drive its global prevalence. As early-stage CKD often remains asymptomatic, late diagnosis and progression to end-stage renal disease (ESRD) impose substantial clinical and economic burdens on healthcare systems, requiring long-term dialysis or organ transplantation.

Governments and health agencies are prioritizing CKD within noncommunicable disease (NCD) strategies due to its chronic trajectory, high treatment costs, and impact on workforce productivity. The shift toward preventive nephrology and early intervention is reinforcing demand for treatment modalities that delay disease progression, manage comorbidities, and reduce complications such as anemia, hyperphosphatemia, and mineral bone disorders. Public awareness campaigns and screening programs are also expanding, particularly in high-risk populations, to promote earlier diagnosis and engagement with treatment pathways.

How Are Pharmacological Advancements and Multi-Target Therapies Shaping CKD Treatment Approaches?

Pharmacological innovation is reshaping the CKD treatment paradigm, with a strong pipeline of novel agents that target disease-modifying pathways rather than solely managing symptoms. Sodium-glucose co-transporter-2 (SGLT2) inhibitors have gained prominence not only for their glycemic control but also for their renal-protective and cardiovascular benefits in both diabetic and non-diabetic CKD populations. These agents, along with nonsteroidal mineralocorticoid receptor antagonists (nsMRAs) and endothelin receptor antagonists, are broadening therapeutic options beyond traditional ACE inhibitors and ARBs.

Combination therapies are increasingly being deployed to address the multifactorial nature of CKD progression, including inflammation, oxidative stress, and proteinuria. Meanwhile, the development of next-generation anemia treatments-such as hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs)-is enhancing outcomes for CKD-related anemia without the risks associated with erythropoiesis-stimulating agents. This multi-target approach is advancing CKD care toward more personalized and disease-specific regimens that emphasize renal function preservation and long-term risk reduction.

Which Delivery Models and Technologies Are Supporting Access and Continuity of CKD Care?

As healthcare systems prioritize early-stage CKD management, integrated care delivery models involving primary care, nephrology, nutrition, and behavioral health are gaining traction. These multidisciplinary programs aim to slow disease progression and optimize management of cardiovascular comorbidities through coordinated, protocol-driven interventions. Dialysis centers are also evolving to offer home-based peritoneal dialysis and hemodialysis options, supporting patient autonomy and reducing the logistical burden on facility-based care infrastructure.

Digital health tools-such as remote monitoring platforms, electronic health records with predictive analytics, and tele-nephrology-are improving continuity of care across geographies. These technologies enable early detection of functional decline, real-time medication adherence monitoring, and timely therapeutic adjustments. In resource-limited settings, mobile health (mHealth) apps and portable diagnostic devices are extending access to nephrology care and education, especially in rural and underserved populations where nephrologist shortages are acute.

How Are Payers and Policymakers Addressing the High Economic Burden of CKD Treatment?

CKD imposes one of the highest per-patient healthcare costs globally, particularly in its late stages where dialysis and transplantation dominate expenditures. As ESRD rates climb, public and private payers are reevaluating reimbursement frameworks to incentivize early intervention, promote cost-effective therapies, and delay dialysis initiation. Bundled payment models and value-based care contracts are being piloted to align provider incentives with patient outcomes in CKD management.

Policy measures are also expanding access to essential medicines, including the inclusion of newer agents in national formularies and reimbursement schemes. In some regions, governments are investing in CKD registries, risk stratification tools, and quality metrics to improve care oversight and resource allocation. Cross-sector collaboration with patient advocacy groups and pharmaceutical manufacturers is supporting medication affordability programs and public education initiatives-aimed at shifting CKD from a silent epidemic to a proactively managed chronic disease.

Can the Chronic Kidney Disease Treatment Market Drive Outcome-Centric Innovation While Addressing Global Disparities?

The path forward for CKD treatment lies in balancing innovation with equity-ensuring that novel therapies, diagnostic tools, and multidisciplinary care frameworks reach patients across all economic strata and healthcare systems. As treatment protocols become more sophisticated and data-driven, healthcare stakeholders must address persistent gaps in access, especially in low- and middle-income countries where diagnosis rates remain low and renal replacement therapies are unaffordable for most.

Achieving sustainable impact will require investment in workforce training, digital infrastructure, public health surveillance, and policy reform. As clinical evidence grows for renal-protective therapies and holistic disease management models, the central question emerges: Can the global CKD treatment market scale equitable, outcome-oriented care fast enough to mitigate long-term human and financial costs-while adapting to emerging science, demographic shifts, and system-level pressures?

SCOPE OF STUDY:

The report analyzes the Chronic Kidney Disease Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment Type (Drug Type, Dialysis); End-Use (Hospitals & Clinics, Dialysis Centers, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

  • AbbVie Inc.
  • Akebia Therapeutics, Inc.
  • Allena Pharmaceuticals
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Cincor Pharma, Inc.
  • DiaMedica Therapeutics Inc.
  • Eli Lilly and Company
  • Fresenius Medical Care AG & Co. KGaA
  • GlaxoSmithKline plc
  • Kibow Biotech, Inc.
  • Lexicon Pharmaceuticals, Inc.
  • Monogram Health
  • Novo Nordisk A/S
  • ProKidney Corp.
  • Reata Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Strive Health

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Chronic Kidney Disease Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Hypertension and Diabetes Drives Growth in CKD Treatment Market
    • Early-Stage CKD Management Gains Attention With Launch of SGLT2 Inhibitors and New Renoprotective Therapies
    • Expansion of Dialysis Infrastructure and Home Hemodialysis Technologies Improves Access to Late-Stage Care
    • Kidney Transplant Program Growth Strengthens Demand for Immunosuppressive and Supportive Therapies
    • Public Health Initiatives Focus on Early Detection and Risk Factor Control in At-Risk Populations
    • Multimodal Treatment Approaches Combine Lifestyle, Pharmacologic, and Digital Interventions
    • Renal Anemia and Mineral Bone Disorder Management Evolve With New Drug Classes and Formulations
    • Biopharma R&D Pipelines Focus on Anti-Inflammatory and Anti-Fibrotic Therapies for CKD
    • Clinical Decision Support Tools and Predictive Algorithms Enhance Progression Monitoring
    • Value-Based Kidney Care Contracts Encourage Outcomes-Driven Innovation in Treatment Delivery
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Chronic Kidney Disease Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Chronic Kidney Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Chronic Kidney Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Drug Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Dialysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Dialysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Dialysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Dialysis Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Dialysis Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Dialysis Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Chronic Kidney Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: USA 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: Canada 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Chronic Kidney Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Japan 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Japan 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Chronic Kidney Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: China 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: China 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Chronic Kidney Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Chronic Kidney Disease Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Europe 15-Year Perspective for Chronic Kidney Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Chronic Kidney Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: France 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: France 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Chronic Kidney Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Germany 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Germany 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Italy 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Italy 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Chronic Kidney Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: UK 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: UK 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Spain 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Spain 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Russia 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Russia 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Chronic Kidney Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Chronic Kidney Disease Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 15-Year Perspective for Chronic Kidney Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Chronic Kidney Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Australia 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Australia 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Chronic Kidney Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: India 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: India 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: South Korea 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: South Korea 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Chronic Kidney Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Chronic Kidney Disease Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Latin America 15-Year Perspective for Chronic Kidney Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Latin America 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Argentina 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Argentina 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Brazil 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Brazil 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Mexico 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Mexico 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Chronic Kidney Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Chronic Kidney Disease Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Middle East 15-Year Perspective for Chronic Kidney Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Middle East 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Iran 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Iran 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Israel 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Israel 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: UAE 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: UAE 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Chronic Kidney Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Africa 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Africa 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION